Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 17/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | PNP | P00491 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9175736 | 1.00 | HPRT1 (0.81) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL173060 | 1.00 | HPRT1 (0.81) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL97316 | 0.92 | HPRT1 (0.75) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL14669187 | 0.91 | HPRT1 (0.71) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL14669071 | 0.91 | HPRT1 (0.71) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL14669070 | 0.91 | HPRT1 (0.71) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL16020658 | 0.91 | HPRT1 (0.81) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL9189420 | 0.91 | HPRT1 (0.81) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL3856994 | 0.91 | HPRT1 (0.81) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL9055551 | 0.90 | HPRT1 (0.66) | HPRT1MEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-6964968-B2 | Method for the treatment or prevention of viral infection using nucleoside analogues | SHIRE BIOCHEM, INC. (CA) | 2005-11-15 | — | — | US | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6583149-B1 | 2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-Dioxolane | BIOCHEM PHARMA INC. (CA) | 2003-06-24 | — | — | US | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |
| US-20250352777-A1 | SUBMUCOSAL BIORESORBABLE DRUG ELUTING PLATFORM | INTERSECT ENT INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12403291-B2 | Submucosal bioresorbable drug eluting platform | INTERSECT ENT, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3791826-B1 | SELF-EXPANDING DEVICES | INTERSECT ENT INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-12064577-B2 | Drug-coated balloon | INTERSECT ENT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240269350-A1 | IMPLANTABLE MATRIX FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | LYRA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240050632-A1 | SELF-EXPANDING DEVICES AND METHODS THEREFOR | INTERSECT ENT, INC | 2024-02-15 | — | — | US | disclosed |
| EP-0452935-B1 | Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1995-06-21 | — | — | EP | disclosed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | disclosed |
| US-5302585-A | Viricides, HIV virus | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-04-12 | — | — | US | disclosed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | disclosed |
| EP-0452935-A1 | Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1991-10-23 | — | — | EP | disclosed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | HPRT1 6/4885MEN1 922/4885ALDH1A1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.